Bioavailability and Pharmacodynamics of Promethazine on Long Duration Missions to the International Space Station by Cintron, Nitza et al.
Bioavailability and Pharmacodynamics of Promethazine on Long Duration 
Missions to the International Space Station 
PI: Lakshmi Putcha, PhD, NASA 
National Aeronautics and Space Administration 
Office of Biological and Physical Research 
Biomedical Research and Countermeasures Program 
Independent Investigator Research Projects 
(NRA 04-OBPR-01) 
Research Opportunities for Flight Experiments in Space Life Sciences 
Title: Bioavailability and Pharmacodynamics of Promethazine on Long 
Duration Missions to the International Space Station 
PRINCIPAL INVESTIGATOR: Lakshmi Putcha, Ph.D. 
Senior Pharmacologist 
SK3/Phamacotherapeutics Laboratory 
Human Adapations and Countermeasures Office 
NASA - Johnson Space Center 
Tel: 28 1-483-7760 
1akshmi.putcha- 1 @nasa.gov 
CO-INVESTIGATORS : 
Jason L. Boyd, Ph.D. 
Universities Space Research Association 
SK3/Phamacotherapeutics Laboratory 
Human Adapations and Countermeasures 
Office 
NASA -Johnson Space Center 
Tel: 281-483-9992 
Fax: 483-3058 
Jboydl @ems.jsc.nasa.gov 
Nitza Cintron, MD 
Flight SurgeodDivision Chief 
Authorizing Institutional Official: 
SWHuman Adaptation and 
Countermeasures Office 
NASA - Johnson Space Center 
Kurt L. Berens 
Pharmacotherapeutics Laboratory 
Wyle Laboratories - Life Sciences Systems 
and Services 
1290 Hercules Drive 
Houston, TX 77058 
Phone: (28 1) 244-2508 
Fax: (281) 483-3058 
Charles F. Sawin, Ph.D. Date 
Chair, JSC Committee for the Protection of Human Subjects 
i 
https://ntrs.nasa.gov/search.jsp?R=20060050319 2019-08-29T23:54:33+00:00Z
Bioavailability and Pharmacodynamics of Promethazine on Long Duration 
Missions to the International Space Station 
PI: Lakshmi Putcha, PhD, NASA 
111. Abstract. Space motion sickness (SMS) is often treated in space with promethazine 
(PMZ). Common side effects of PMZ administration (50 mg intramuscular) on the 
ground are drowsiness and impaired cognitive performance. Anecdotal reports indicate 
that these effects are absent or less pronounced in space. This suggests that the 
availability of PMZ to the body (bioavailability) and/or the response of the body to PMZ 
(pharmacodynamics) may change during space flight. Opportunities for clinical research 
in space are limited. The study described here is our response to a NASA Research 
Announcement for proposals for flight-based research needed to improve, or answer 
specific questions about, diagnosis and therapy during space flight, and post-flight 
rehabilitation. 
We propose here to evaluate noninvasive methods for determining the 
bioavailability and pharmacodynamics of PMZ. The specific objectives of the proposed 
research are to 1) compare pharmacokinetic and pharmacodynamic parameters of PMZ, 
estimated from saliva and plasma levels after administration of PMZ, 2) estimate the 
relative bioavailability of the three dosage forms of PMZ that are often administered to 
control motion sickness symptoms in space, and 3) establish the dose-response 
relationship of PMZ. 
We will estimate the bioavailability of an intramuscular injection (IM), oral tablet, 
and rectal suppository of PMZ in noma1 subjects during ambulatory and antiorthostatic 
bed rest (ABR) conditions using novel stable isotope techniques. We will compare and 
contrast the bioavailability of PMZ during normal and microgravity conditions to 
examine changes in drug absorption and bioavailability during microgravit. Results of 
this study will validate methods for an approved in-flight investigation with this 
medication awaiting an opportunity for manifestation.. 
IV. Specific Aims. These are the working hypotheses of this project: 
A. Relative bioavailability of PMZ from different routes of administration 
can be estimated by simultaneous administration of three different stable 
isotopic forms of PMZ. 
B. A consistent ratio between saliva and plasma concentrations of PMZ 
exists following all routes of administration of PMZ. This ratio may be 
altered during spaceflight. 
C. Spaceflight will induce changes in the absorption, bioavailability, and 
pharmacodynamics of PMZ. 
The overall goal of the proposed research is to characterize the pharmacotherapeutic 
profile of PMZ in spaceflight. The study will be conducted with 12 astronauts or 
cosmonauts, with an equal number of each gender. These are the specific aims 
designed to achieve the research goal: 
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Specific Aim 1. During ground and spaceflight conditions and using stable isotope 
formulations, estimate the bioavailability of PMZ after 
administration by intramuscular, oral, and rectal routes. 
Specific Aim 2.  After collecting saliva and blood samples, determine the saliva-to- 
blood plasma ratio of PMZ. Validate the feasibility and reliability 
of using saliva levels of PMZ as a noninvasive method to study the 
pharmacokinetics and pharmacodynamics of PMZ in space. 
Specific Aim 3. Examine the effect of spaceflight on the absorption, bioavailability, 
and pharmacodynamics of PMZ. 
Specific Aim 4. Establish noninvasive methods for determining the 
pharmacodynamics of PM. These methods may include collecting 
saliva samples, administering cognitive performance tests, and 
using activity monitoring devices. 
V. 
in a given dosage form, under any condition, is a function of the agent's intrinsic activity 
and its concentration at the site of action. The onset, intensity, and duration of the 
pharmacological response produced by a drug, collectively known as that drug's 
pharmacodynamics, depend upon the processes that affect its concentration, namely, 
absorption, distribution, metabolism, and elimination. The mathematical description of 
these processes and their interrelationships are known as that drug's pharmacokinetics. In 
general, understanding the kinetics and dynamics of a drug allows the development of 
effective dosage regimens; allows appropriate adjustments for variations among 
individuals; and allows appropriate corrective actions in the event of an unusual response 
to that drug. Both pharmacokinetic and dependent pharmacodynamic parameters (e.g., 
bioavailability, clearance, and onset, magnitude, and duration of effect) are influenced by 
many physicochemical, biological, and clinical factors. These factors include but are not 
limited to subject's gastrointestinal, hepatic, and renal function, body weight and size, 
disease state, as well as a drug's protein-binding characteristics, and its interaction with 
other drugs administered simultaneously. 
Background and Significance. The biological effect elicited by a therapeutic agent 
Exposure to microgravity causes complex physiological changes in humans. The degree 
and magnitude of these changes probably vary with mission length and other mission- 
related factors. These physiological changes in turn induce therapeutically significant 
changes in the pharmacology of drugs used during space flight. Changes in 
gastrointestinal function, redistribution of body fluids, and changes in hepatic and renal 
function are known to affect drug absorption, distribution, metabolism, and elimination 
(Bennett et al., 1978; Klotz, 1976; Levine, 1970; Wilkinson, 1976; Williams and 
Namelok, 1980). Since orbital space flight is known or suspected to affect all of these 
systems, it is very important to characterize the induced changes and associated 
pharmacological consequences in order to develop effective treatments for in-flight 
pathologic incidents. 
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Pharmacokinetics in space. Conventional methods of collecting pharmacokinetic 
information require multiple blood samples to determine drug concentrations in the body 
over time. As an alternative to this invasive procedure, which is also difficult to perform 
in microgravity, saliva was found to be useful for estimating drug bioavailability of many 
drugs like acetaminophen and scopolamine. The validity of using drug concentrations in 
saliva to predict blood levels depends on both the concentration of a drug that appears in 
saliva and the consistency of its saliva-to-plasma (SP) ratio over a range of plasma 
concentrations (Graham, 1982). Many weakly basic drugs distribute readily into saliva at 
measurable concentrations (Danhof and Breimer, 1978). Salivary concentrations of 
highly protein-bound drugs represent the active (unbound) form of the drug, while 
plasma concentrations represent both active and bound fractions (Vesell et al., 1975). 
Limited results from ground-based simulation studies and preliminary flight studies using 
saliva to monitor acetaminophen and scopolamine suggest that microgravity induces 
changes in the absorption of drugs after oral administration (Cintrh et al., 1987; Putcha 
et al., 1989; Putcha and Cintrh, 1991). Since absorption is directly related to 
bioavailability, a change in absorption can potentially affect a drug's anticipated 
therapeutic effect by altering the rate of onset, the magnitude, or the duration of that 
effect. It is suspected that changes in GI function associated with microgravity are at 
least partially responsible for altering absorption patterns. Because GI function directly 
influences the absorption of nutrients and fluids as well as drugs, alterations in GI 
function will become more important as space missions become longer. 
Ground-based analogs for microgravity. Flight opportunities to conduct space research 
are limited and require prolonged periods of preparation before implementation. 
Therefore, researchers have used ground-based microgravity analogs to simulate 
physiological and biochemical changes similar to those observed during space flight. 
The most widely used simulation model of space flight environment for human research 
is bed rest, both horizontal and head-down (antiorthostatic) posture (Nicogossian et al., 
1979). Bed rest has been reported to induce many physiologic changes that are similar to 
those observed in space such as muscle atrophy, bone demineralization, redistribution of 
fluids and body mass, and decreases in plasma volume and red blood cell mass (Genin, 
1977; Sandler, 1976; Sandler and Vernikos, 1986). On the other hand, antiorthostatic bed 
rest (ABR) elicits some of the early physiological effects of microgravity more precisely 
than the horizontal bed rest (Kakurin et al., 1976). In particular, ABR results in more 
rapid and pronounced fluid shifts and resultant cardiovascular changes (Blomquist et al., 
1980). 
In a study on the effects of ABR on physiology and metabolism in human subjects, ABR 
has been shown to induce changes in gastrointestinal (GI) motility similar to those 
observed in a limited number of crewmembers during space flight. (Putcha, 199 1 ; Lane, 
et al., 1999). A physiologically based pharmacokinetic model for acetaminophen was 
constructed using data from this study and similar data collected during space flight were 
fitted to this model. A high degree of correlation was noticed between these data 
indicating that ABR may be a good surrogate for microgravity (Srinivasan et al., 1994). 
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Since absorption and bioavailability of oral medications are dependent on GI motility, 
and for drugs that have relatively low bioavailability from an oral dose like scopolamine 
and PMZ, ABR may serve as an effective simulation model to examine bioavailability 
changes of these drugs during space flight. Another fact that supports the use of ABR for 
bioavailability evaluations of SMS medications is that it induces early physiological 
effects of microgravity, and SMS is manifested during early flight days. 
Pharmacology of space motion sickness. Approximately 70% of Space Shuttle 
crewmembers experience symptoms of SMS during the first few days of flight. These 
symptoms can include malaise, anorexia, headache, lack of motivation, impaired 
concentration, stomach awareness, and vomiting (Reschke et al., 1994). The frequency 
and severity of SMS symptoms has led to restrictions on extravehicular activities (no 
sooner than 72 hours after launch) and mission duration (no less than 3 days). 
Tests on Earth suggest that motion sickness is associated with a profound reduction in 
gastric emptying (Stewart et al., 1993; Wood et al., 1987). Although the specific 
mechanisms remain unknown, a reduction in gastric emptying typically has two effects on 
orally administered drugs: a delay in the time of peak concentration and a reduction in the 
peak concentration of drug in blood (Nimmo, 198 1). These changes affect thc rate and 
extent of a drug's pharmacodynamic effect, which may partially explain why some orally 
administered drugs seem to be less effective in space. However, many other factors 
typical of space flight, such as cephalad fluid shifts, cardiovascular changes, changes in 
cabin pressure, and dehydration, will influence drug absorption and metabolism from any 
route of administration (Santy and Bungo, 1991). 
Numerous medications have been used, with varying success, to treat SMS symptoms. 
Currently, PMZ is the antimotion sickness drug of choice for Space Shuttle missions, and 
has a reported 75% efficacy via the intramuscular route (Davis et al., 1993). PMZ, a 
phenothiazine and an H-1 antihistamine, is used before and after surgery as an adjunct to 
analgesia and for its sedative and antihistaminic effects. PMZ can be given intravenously 
(IV), orally (PO), intramuscularly (IM), or as a suppository. PMZ's moderate 
anticholinergic effects are thought to be the source of its antimotion sickness activity 
(Wood and Graybiel, 1972). Typical side effects include dizziness, drowsiness, sedation 
and impaired psychomotor performance (all typical of anticholinergics); extrapyramidal 
and dystonic reactions are typical of phenothiazines and other dopaminergic receptor 
antagonists. 
Pharmacokinetics and bioavailability of PMZ. The pharmacokinetics of PMZ have been 
characterized after IVY PO, and IM doses. After IV doses, plasma levels decline 
exponentially with a terminal elimination half-life of 7 to 14 hours (Taylor et al., 1983). 
Absolute bioavailability after an oral dose is low, averaging approximately 22-25 percent, 
with plasma concentrations peaking 6 to 12 hours aAer PO or IM doses; peak plasma 
concentrations after IM administration are about 4 times those after an equivalent PO 
dose. PMZ's low bioavailability after oral administration may be due to significant first 
pass metabolism and/or poor absorption from the gut. PMZ has a large volume of 
distribution (970 L) and is about 80 percent protein bound. It is cleared from the body by 
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hepatic metabolism; promethazine sulfoxide is the major metabolite and 
desmethylpromethazine is a minor metabolite. Less than one percent of the drug is 
eliminated unchanged in the urine. The saliva (parotid) to whole blood ratio is about 0.24 
aAer IM and 0.20 after PO administration (DiGregorio and Ruch, 1980, Taylor et al., 
1983). 
Novel cZinica1 research technologies. Conventional pharmacokinetics and bioavailability 
studies described above are conducted using extensive crossover study designs with 
multiple treatment sessions that prolong the experimental period and often compromise 
subject compliance. Such crossover studies are based on the assumption that a drug's 
clearance is constant over long periods of time and have minimal intra-individual 
variability throughout the study. Unfortunately, these studies also require a large number 
of subjects for long time periods in order to minimize subject variability and maximize 
reliability of results. Studies with drugs where systemic clearance is strongly influenced 
by factors such as posture, GI function, or blood flow changes to the eliminating organ, 
the assumption of constant clearance may no longer be valid and a simple crossover 
design is neither appropriate nor practical (Powell, 1997). Additionally, because hepatic 
metabolism is characterized by high inter- and intra-individual variability, it is often 
difficult to extrapolate clearance either between two doses in the same individual or two 
doses in two individuals (Lesko etal, 2000). Further, these study designs may be also 
inappropriate for similar investigations in space flight due to the anticipated dynamic 
organ function and blood flow changes induced by the microgravity environment. 
This simultaneous administration of SIL and unlabeled PMZ protocol has been selected 
because of reports using similar protocols (Gilbert, et al., 1998; Browne, et al., 1993) for 
bioavailability and bioequivalency studies. These investigators used an unlabeled drug 
with two labeled drug forms (timolol and phenytoin) in their studies. 
The advent of LC-MS technology has led to the development of novel approaches using 
stable isotope labeled (SIL) drug analogs in clinical biomedical research. Mass 
spectrometry (MS) has been the premier technique for the detection, structure 
determination and quantitation of compounds labeled with stable isotopes. The on-line 
combined technique of liquid chromatography-mass spectrometry (LC-MS) provides the 
advantages of both high performance liquid chromatography (HPLC) and mass 
spectrometry. LC-MS is widely recognized as the most powerful tool available for the 
analysis of low concentrations of drugs and their metabolites in biological matrices, with 
high sensitivity and specificity. The ability of LC-MS to distinguish and measure 
compounds (drugs & metabolites) labeled with stable isotopes with such analytical 
prowess, makes this technique the obvious choice when tracer studies with 
pharmaceuticals are considered (Evans, 1997). As a result, SIL formulations have been 
successfully employed by the pharmaceutical industry and by clinical researchers for the 
assessment of absolute and relative bioavailability of drugs (Gilbert, et al., 1998; Powell, 
1997). SIL forms commonly used for clinical pharmacokinetic studies are deuterium, 13C, 
''N and '*O. Careful selection of the type and location of isotope label, and simultaneous 
administration of the labeled and unlabeled drug forms will avoid metabolic isotope effect 
and other related isotope effects on phamacokinetics and bioavailability measurements. 
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Study designs utilizing SIL techniques offer greater statistical power and less intra- 
individual variability for bioavailability assessments of drugs (Gilbert, et al., 1998; 
Powell, 1997; Browne, et al., 1998). The most important advantage of these techniques is 
subject safety enhanced by the absence of ionizing radiation doses, and reduction in 
sample requirements since multiple formulations of a drug in different SIL forms can be 
administered simultaneously and circulating concentrations measured in a single sample 
using LC-MS techniques (Klein, 1997). These studies also offer higher statistical power 
for detecting changes since inter-subj ect variability between treatments is eliminated by 
simultaneous administration of test doses. 
Pharmacodynamics and side erects of PMZ. Surprisingly, there is very limited 
information available on the pharmacodynamics of PMZ, while there are a number of 
reports on the side effects of the medication. Although any side effect can be problematic 
in space, none can endanger crew safety more than the impairment in psychomotor 
performance. Space crews often must perform complex, exacting tasks during the first 
few days in space, when SMS symptoms are worst. Crews' cognitive, motor, and 
perceptual skills must be preserved in space. Oral doses of PMZ (12.5 to 25 mg) on Earth 
are known to impair psychomotor performance, information processing, and feelings of 
alertness, with deficits peaking within 3 to 4 hours after dosing and that lasted for as long 
as 8 to 9 hours (Parrott and Wesnes, 1987). PMZ also impairs performance on 
operationally structured tests (Hyman et al., 1988; Schroeder et al., 1985). In a recent 
study on the effects of PMZ (30 mg PO), cognitive and psychomotor function in normal 
subjects was impaired as indicated by a significant reduction in critical flicker fusion 
threshold and an increase in recognition reaction time and percent day time-sleep like 
activity (Hindmarch et al. 1999). 
Anecdotal reports of PMZ users during flight suggest that the central nervous system 
(CNS) effects of this drug may be attenuated in space (Bagian, 1991; Davis et al., 1993). 
Objective assessment of performance-related effects, in combination with bioavailability, 
will promote the establishment of safe and effective doses for PMZ in space. We, 
therefore, propose a systematic evaluation of the bioavailability and pharmacokinetics of 
PMZ in conjunction with an assessment of the drug's pharmacodynamic effects, 
especially the performance decrements, in astronauts on long duration missions to the 
International Space Station. 
VI. Preliminary Studies. We evaluated in-flight use of medications from astronaut 
debriefings after 79 U.S. Space Shuttle missions (Putcha, et al., 1999). From the 219 
records obtained (each representing one person-flight), 94% included some medication 
being taken during flight; of that number, 47% were for space motion sickness, 45% for 
sleep disturbances, and smaller percentages for headache, backache, and sinus congestion. 
Drugs were given most often orally, followed in decreasing order of frequency by 
intranasal, intramuscular, and rectal routes. Promethazine (PMZ) is the only drug that is 
given by three different routes, oral, intramuscular, and rectal during space flight. Since 
motion sickness has been one of the major discomforts during short duration space flights, 
and scopolamine and PMZ are identified as the drugs of choice for the treatment of this 
ailment, we examined the pharmacokinetics of these two drugs. Antiorthostatic bed rest 
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(ABR) has been used for validating noninvasive methods and for evaluating some of the 
physiological and pharmacokinetic changes using these noninvasive methods. Results 
from some of these studies are presented here. 
Scopolamine. Scopolamine is used to alleviate SMS symptoms in space. The drug has 
poor and variable oral bioavailability (Putcha et al., 1989). We evaluated the 
pharmacokinetics of orally (PO) and intravenously (IV) administered scopolamine after 
24 h of ABR to examine the drug’s oral bioavailability in a simulated microgravity 
environment. Pharmacokinetic analysis indicated significant decreases in the absorption 
and bioavailability of oral scopolamine (Putcha et al., 1989); distribution and elimination 
of intravenous scopolamine were no different during ABR than in the controls. These 
results were in agreement with results from a similar investigation during space flight. 
During ABR and during space flight, absorption and bioavailability of scopolamine were 
decreased; whereas, distribution and elimination of the drug were not different from the 
respective controls (Cintr6n et al., 1987). These data suggest that ABR, even for a short 
duration of 24 h can simulate changes in drug bioavailability similar to the ones observed 
during space flight. 
Based on these results, we examined the effect of Al3R on gastrointestinal function, a key 
physiological factor of absorption and bioavailability of orally administered drugs. We 
validated a noninvasive breath hydrogen test in conjunction with acetaminophen 
absorption test to estimate changes in gastrointestinal (GI) motility and absorption during 
ABR and during space flight. Results from these studies indicate that GI motility during 
ABR and during short and long duration space flights was reduced significantly and ABR 
simulated changes in the GI motility and absorption similar to the ones noticed during 
limited space flight experiments (Putcha, 1991; Lane et al., 1999). A physiologically 
based pharmacokinetic model for acetaminophen was constructed using data from the 
ABR study and the model was fit to data collected during space flight. A strong 
correlation was noticed between model-predicted and space flight data indicating that 
ABR may be a good surrogate for microgravity for absorption and bioavailability studies. 
Promethazine. In a recent pilot study on methods validation in support of an approved 
flight investigation, we evaluated the pharmacokinetics and pharmacodynamic effects of 
a single intramuscular administration of PMZ (50 mg) in commercial airline pilots trained 
to operate a space shuttle landing simulator. A single dose of 50 mg induced a 
statistically significant increase in perceived drowsiness at 1 , 4, and 8 hours after 
administration compared to placebo controls. Similarly, Stanford Sleep Scale Scores 
were significantly higher at 1 ,2  and 4 hours after PMZ administration compared to 
placebo controls. These results suggest that a 50 mg intramuscular dose of PMZ can 
induce drowsiness in pilots that lasted up to at least 4 h after administration. 
For estimating metabolite levels, an on-line solid phase extraction (SPE) liquid 
chromatographic (LC) method using column-switching system has been developed and 
utilized for the simultaneous measurement of PMZ and its metabolites. The method 
employs direct injection of human urine into an on-line SPE column for the effective 
removal of matrix interference, which allows the enrichment of the analytes. The use of 
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on-line SPE resulted in reduced sample preparation time, cleaner extract and greater 
reproducibility. The linear dynamic range covered was from 1 to 1200 ng/ml with a 
correlation coefficient of 0.999 (using 1/X as a weighting factor). The limit of detection 
(LOD) of this assay using UV detection varied from 4.25 to 5.39 ng/ml. And the 
sensitivity was enhanced to the picogram level using fluorescence detection with an 
excitation wavelength at 254nm and emission wavelength 425nm (LOD 285 pg/ml for 
PMZ and 248 pg/ml for desmethyl PMZ). Quantitative data demonstrate that the assay is 
specific, precise, accurate, and robust with a wide concentration range. A publication 
describing the new method has been accepted for publication in the J of Chromatogrphy. 
We also examined in this study, the saliva to plasma ratio of the parent compound (PMZ) 
and a major metabolite (PMZ sulfoxide). As seen in the representative profiles of saliva 
and plasma in one subject, a consistent ratio between saliva and plasma exists for both the 
compounds, however, the ratio is approximately 0.8 for PMZ sulfoxide while it is about 
PMZ Levels -Subject 3, Trial 2 
I j- . E 30 
5 25 0 
= 5  
-17 
0 2 4 6 8 10 
~ Time (hours) 
Figure 1A: Plasma and saliva levels of PMZ; determined by HPLC with UV 
detection. 
I 1 
Figure 1B: Plasma and saliva levels of PMZ sulfoxide; determined by HPLC with 
UV detection. 
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0.4 for PMZ (Figures 1A & B). Results from this study, however, will not provide 
information regarding changes in this ratio that may be anticipated in a microgravity 
environment. 
In preparation for the proposed research, we procured one SIL PMZ +4 form, deuterated 
at the 1, 3,7,  and 9 position on the aromatic rings (C/D/N Isotopes, Point-Claire, Quebec, 
Canada) for the development and validation of an LC/MS assay to quantitate PMZ and 
+4 PMZ. As shown in Figures 2, selective ion monitoring of authentic standards of PMZ, 
deuterated PMZ, and trifluoperazine (internal standard) is used to quantitate PMZ levels. 
The linear dynamic range covered with this assay is from 5 to 300 ng/ml (Figure 3). This 
assay, in conjunction with the Waters Alliance/ Micromass 2-spray LC-MS, will be 
employed for the simultaneous determination of unlabeled PMZ, SIL +4 PMZ and SIL 
+7 PMZ, and their respective labeled and unlabeled metabolites in the Phase I 
bioavailability study. 
In a separate, ongoing study in our lab investigating the bioavailability and 
pharmacodynamics of PMZ in human subjects in both ambulatory and ABR scenarios, 
PMZ was found to significantly affect several aspects of cognitive performance, as 
measured by the ARES and WinSCAT cognitive performance software tools. Time to 
accurately complete memory tasks was found to increase significantly with 
concentrations. Higher concentrations also increased response time and decreased 
accuracy of substitution and matching tasks. AUC and half-life estimates for PMZ ranged 
between 0.12 and 1.7 mg.WL and 15 and 50 h, respectively. 
The simultaneous administration of SIL formulations of PMZ in this study have shown 
that oral administration in an ambulatory setting provides the longest exposure time to 
PMZ, likely because much of the PMZ is immediately metabolized to conjugates which 
are then excreted into the gut, metabolized there by bacterial flora or intestinal 
cytochromes back to the parent compound, PMZ, and then reabsorbed into the circulation 
in a process called enterohepatic recycling. Because of this recycling, peak 
concentrations may occur more than 24 hours after the initial dose in subjects who have a 
high propensity to excrete via conjugation, such as females and certain ethnic groups. 
During ABR however, intramuscular administration (to the buttocks) produced the 
highest bioavailability, 26 and 13 times higher than rectal suppository or oral capsule. 
Finally, PMZ may exhibit dose-dependent pharmacokinetics in humans as AUC 
increased disproportionately with dose, a common feature of drugs excreted by 
conjugation. 
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Sleep and activity measurements. We have used and validated in a related investigation, 
the methods we propose to collect sleep and performance parameters in this study. We 
examined the sleep quality by measuring sleep-related parameters in astronauts working 
on altered work-sleep schedules aboard the space shuttle. Sleep parameters were 
measured using wrist actigraphy before flight, during preflight light treatment period, and 
after flight. The data generated by the actigraph were analyzed for the sleep-wake cycle, 
the quality of rest (number of minutes awake after sleep onset), and sleep to wake ratio 
(Putcha, et al., 1997). Results of this study suggested that actigraphy could successfully 
detect changes in sleep intensity and quality. Based on this experience, and on a recent 
report that actigraphy is a sensitive measure for assessing drug induced changes in 
percent daytime activity and sleep (Stanley, 1997), we plan to use these methods in the 
proposed investigation to collect data on the parameters described above. 
Bioavailability and Pharmacodynamics of Promethazine on Long Duration 
Missions to the International Space Station 
PI: Lakshmi Putcha, PhD, NASA 
Cognitive performance measurement tool. The WinSCAT (Windows based Shuttle 
Cognitive Activity Test) was developed exclusively for space flight-specific cognitive 
activity testing. WinSCAT has been used by astronauts during the NASA-7 mission to 
Space Station Mir and during the Lunarmars Life Support Test Project (LMSTP) to 
validate sensitivity and applicability to shuttle operational testing. A study to validate the 
WinSCAT against widely used neurocognitive measures (Letter-number Sequence, Digit 
Symbol, Digit Symbol Incidental Memory, Figural Memory, Paired Associate Learning, 
Trails By and Paced Serial Addition Test) was conducted in young adults. Results of this 
study indicated that there is a significant relationship between the WinSCAT tests and the 
widely used tests of neuropsychological function. Another study was conducted to assess 
the sensitivity of WinSCAT to detect hypoxia effects on performance, results indicated a 
significant difference in WinSCAT scores with subjects breathing hypoxic air equal to 
15,000 feet mean sea level and nonnoxic air. However, in a study with subjects 
completing a military survival course indicated that WinSCAT scores were not sensitive 
to high fatigue as measured by other fatigue measurements. A study to examine the 
learning effects and score stability using WinSCAT in 60 medical students over a one- 
year period is in progress at this time. We are encouraged by the applicability of the 
WinSCAT for detecting neurocognitive effects of these above mentioned off-nominal 
conditions and are proposing to use the test for pharmacodynamic evaluation of PMZ. 
VII. Research Design and Methods. This research protocol is designed in response to 
the NASA Research Announcement charge for flight experiments to investigate critical 
aspects of biology and medicine in spaceflight, in preparation for upcoming missions to 
the Moon and Mars. The proposed protocol utilizes novel methods for the assessment of 
pharmacodynamics and estimation of bioavailability changes during space flight. 
Further, it is aimed at developing and validating noninvasive methods to characterize 
pharmacodynamic effects of neurosensory medications in general, and PMZ in particular. 
a. Study design overview. The protocol is designed to estimate the bioavailability of 
PMZ using novel stable isotope label (SIL) techniques that minimize subject 
experimentation time and exposure to risk. This study is designed so that intra-subject 
variability is minimized, thereby improving estimates of relative bioavailability of 
multiple dosage forms in individual subjects. A total of 12 astronauts will participate in 
the study. 
The study consists of four sessions: 1) pre-flight, 2) FD3,3) FDlO, and 4) FD120. Each 
session consists of 72 h of sample and data collection. 
Each subject will receive, simultaneously, an intramuscular (IM) injection (12.5 mg) of 
unlabeled PMZ, an oral (PO) capsule (12.5 mg) of stable isotope labeled (SIL) PMZ (+4) 
and a rectal suppository (12.5 mg) of SIL PMZ (+7), once during each session. The PMZ 
doses were selected so that the combined bolus dose does not exceed the maximum 
recommended therapeutic dose of 50 mg. 
ii 
Bioavailability and Pharmacodynamics of Promethazine on Long Duration 
Missions to the International Space Station 
PI: Lakshmi Putcha, PhD, NASA 
Baseline Data Collection: Session one is for baseline data collection. Pharmacokinetics 
of promethazine will be determined on the ground at a time before mission preparation 
and be used as a comparison for early flight and later flight days. 
Table 1 : Experimental Design for Phase and Treatment Levels 
Subject # Treatment Treatment Treatment Treatment 
1 TO T1 T2 T3 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 T2 T1 T3 TO 
TO: placebo; T1: 12.5 mg PMZ; T2: 25 mg PMZ; T3: 50 mg PMZ 
T1 TO 
T2 T3 
T3 T2 
TO T2 
T2 TO 
T3 T1 
T1 T3 
TO T3 
T3 TO 
T1 T2 
T3 T2 
TO T1 
T1 TO 
T3 T1 
T1 T3 
TO T2 
T2 TO 
T1 T2 
T2 T1 
TO T3 
b. Subjects. Twelve 
years will participate in 
inclusion and exclusion 
healthy, non-smoking astronauts between the ages of 21 and 45 
the study. All subjects will be screened and selected to the 
criteria listed below. 
Inclusion criteria: 
1. Male or female 
2. Age 21-45 
3. 
4. 
5. 
6. 
Normal weight for body size 
General good health, as determined by an Air Force Class I11 Flight Physical 
Renal and hepatic function within normal ranges 
Able to provide written informed consent to participate 
Exclusion criteria: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Drug allergies, especially to phenothiazine-type agents 
Use of prescription or over-the-counter medications within 3 days of starting the 
study 
Use of an investigational drug within 30 days of starting the study 
Tobacco smoking within the past year 
Blood donation or significant blood loss within 30 days of starting the study 
Significant gastrointestinal disorder, asthma, or seizure disorders 
History of alcohol or other drug abuse 
Pregnancy or suspected pregnancy, or lactation 
Treatment during menstruation will be avoided 
Hematocrit values less than 41% for males and 37% for females 
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c. Procedures. 
Promethazine Dosage Forms. Two deuterated forms of PMZ (Figure 5) will be 
manufactured and supplied by ISOTEC Inc. (Miamisburg, OH) along with appropriate 
USP purity and isotope enrichment data. Capsules (opaque #6) will be formulated using 
+4 PMZ (12.5 mg) and dextrose; suppositories will be formulated using +7 PMZ (12.5 
mg) with standard ingredients for suppository formulation and according to standard 
practice in compounding. IM PMZ will be purchased from Wyeth-Ayerst (Philadelphia, 
PA). Ten dosages from each formulation will be analyzed for verification of PMZ content. 
The oral and suppository formulations will be prepared under regulatory guidelines in an 
accredited pharmacy by a a pharmacist licensed in the state of Texas using GMP 
guidelines. An IND approval for the SIL dosage forms from the FDA is not necessary 
before implementation of this study. Since the dosing routes proposed in this study are 
FDA approved for PMZ administration and since the combined dose of administration is 
within the therapeutic range, no difference is expected in the pharmacologic and 
toxicologic profiles of PMZ and the two deuterated forms. 
Deuterium substitution at the specific labeling sites for the +4 and +7 deuterated isotopes 
of PMZ was chosen for the following reasons: deuterium is safe, inexpensive compared to 
other stable isotopes (I3C, 15N), and the isotopes are easy to synthesize. The most 
important reason, however, is to avoid metabolic isotope effects. The proplyamine side 
chain of the PMZ molecule is not metabolized. Demethylation only takes place at the N 
terminal methyl groups. The +12 PMZ isotopomer that is deuterated at both N terminal 
methyl groups is used solely as an analytical internal standard for the LC-MS assay. The 
mass difference between PMZ and the subsequent SIL PMZ forms is three atomic mass 
units, which is ideal since no ion overlap between any of the PMZ forms is anticipated. 
Figure 2 shows the mass spectra (obtained on the Alliance LC-MS system) for unlabeled 
PMZ with a strong molecular ion at m/z 285. The +4 PMZ and +7 PMZ forms will be 
measured as molecular ions at m/z 288 and m/z 291 respectively, and 
are expected to have clean strong signals similar to the one depicted for PMZ and +4 PMZ 
in the related research section (Figure 2). 
Treatment: Subjects will receive simultaneously an IM injection (12.5 mg), an oral 
capsule (12.5 mg) and a rectal suppository (12.5 mg) of PMZ as unlabeled and the two 
SIL forms of PMZ, respectively. The treatments will be administered on separate days 
once during each session. All treatments will be administered in the morning to avoid 
variability due to circadian rhythms. Uniform bed times and meal times will be 
maintained during the experimental period. The experimental 
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Collection Times 
+3 PMZ, (D, Promethazine) 
Figure 5: SIL forms of PMZ 
showing deuterium (2H) substi- 
tution of the proteium (H) atoms on 
the PMZ molecule. Deuterium is 
represented as D in the molecular 
structures. 
+I2 PMZ, ( D , ~  Promethazine) 
(LCMS Internal Standard) 
design includes serial blood and saliva sampling, and void-by-void urine collections after 
administration of PMZ. 
Blood, saliva, and urine samples will be collected on experiment days according to the 
schedule in Table 2. Blood samples (7 mL) will be collected into heparinized vacutainers 
from an indwelling catheter placed in the antecubital vein of the arm. The volume of 
blood has been determined, based on the volume required for the determinations of parent 
drug forms and metabolite concentrations for each sessiodtreatment of each phase. A 
total of 504 ml of blood will be collected over the entire study period from each subject at 
four sessions x 18 draws/session x7 ml/draw; each 72 h sample collection period will 
require 126 ml. Stimulated mixed saliva samples will be collected using SalivettesB 
(Sarstedt Inc.). Blood samples will be centrifuged at 3000 rpm, samples transferred to 
cryotubes and stored frozen at -7OOC until analyzed. Urine samples will be collected into 
labeled polycarbonate bottles, volumes measured, and aliquots (30 ml) will be stored 
frozen at -7OOC for future analysis. 
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0,0.25, 0.5, 0.75, 1.0, 1.5, 2, 3,4,  8, 12,24,30,36,48, 
54,60 and 72 h post dose 
Pre-dose & PRN voids for 72 h post dose 
Pre-dose & immediately following each blood draw 
beginning 3 h post dose. 
Pre-dose & immediately following each blood draw. 
Pre-dose & immediately preceding each blood draw. 
Continuous for 72 h post dose 
Sample Analyses. Concentrations of PMZ and metabolites in plasma, saliva, and urine 
will be determined with a modified liquid chromatography-mass spectrometry (LC-MS) 
method described in the Preliminary Studies section of this proposal. This method uses an 
on-line solid-phase extraction coupled with the LC-MS system. The assay involves 
trapping the analytes onto the extraction column, whereas the urine/plasma matrix are 
washed out, and column switching valve then turns onto the analytical column, where 
analytes are eluted in back-flushing mode and resolved within the analytical column. The 
method allows for automated sample clean up and trace enrichment, as well as provides 
more reproducible results. Concentrations of PMZ, PMZ sulfoxide, desmethyl PMZ 
sulfoxide, and desmethyl PMZ will be determined in plasma and urine; while PMZ and 
PMZ sulfoxide will be determined in saliva. LC-MS analysis of the samples will allow 
determination of concentrations of the non-isotopic and the two SIL PMZ parent 
compounds and corresponding metabolites. 
Cognitive Performance Testing. WinSCAT is a Windows-based battery of neurocognitive 
assessment tests that have been validated for different clinical paradigms. Its purpose is to 
allow researchers and behavioral health care providers a means to objectively evaluate 
neurocognitive function. It consists of five tests excerpted and modified from the 
Automated Neuorcognitive Assessment Metrics (ANAM) battery of tests developed by 
the U.S. Navy (Levinson and Reeves,l994; Reeves et al., 1993). It is a clinical assessment 
tool designed for repeated measurements. The WinSCAT is a Windows based program 
and takes about 10-15 minutes to complete the test battery. ARES is a Palm based battery 
of neurocognitive assessment tests similar to WinSCAT. It implements three tests 
exerpted and modified from ANAM. The types of functions evaluated by these tests 
include memory and immediate recall, sustained concentration and attention, verbal 
working memory, visual working memory and math skills. Subjects will be asked to take 
the test batteries at least six times during the base line data collection period of the study 
prior to the initiation of experimentation. They may be asked to attend three 60-minute 
training sessions before the study begins. 
Karolinska Sleepiness Score (KSS). Drowsiness caused by the drug will be measured by 
subjective sleepiness reports using KSS. Sleep researchers commonly use the KSS to 
evaluate subjective alertness/sleepiness and this is sensitive to impairments caused by 
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sleep deprivation and circadian variations. We will use the test results to assess PMZ 
effects. 
d. Data analysis and anticipated conclusions 
Pharmacokinetic and Pharmacodynamic Analyses. Concentration vs. time curves will be 
generated for the unlabeled and SIL PMZ analogs, and their respective metabolite(s) in 
plasma and urine, these data will be analyzed by standard pharmacokinetic data analysis 
programs like RSTRIP (MicroMath Scientific, Salt Lake City, UT), WinNonlin 
(Pharsight Corp., Mountain View, CA) and Boomer (Bourne, 1989), a nonlinear 
regression analysis program. Absorption and elimination rates will be calculated using 
noncompartmental parametric estimation methods. Bioavailability will be calculated 
from the area under the plasma and saliva concentration-time curves (Gibaldi and Pemer, 
1982) of the parent compounds using WinNonlin software. Pharmacodynamic effect(s) as 
a function of drug concentration will be assessed using results from the WinSCAT test 
scores, actigraphy and KSS data, and physiological variables data. Standard 
pharmacodynamic analytical methods (Ross, 1990) will be employed to estimate onset, 
duration and extent of effect, time for minimum and maximum effect, and dose-response 
relationship of the drug. 
Actigraphy data will be reduced using vendor-provided software (Mini Mitter, Inc., 
Bend, OR) after downloading to a PC via serial port. Sleep and activity parameters 
(percent daytime activity, sleep latency, wake after sleep onset, duration and efficiency) 
can be calculated and the effect of PMZ on these parameters evaluated. These objective 
sleep data will be compared with the data from subjective sleep logs. 
WinSCAT is designed to provide an immediate feedback of cognitive performance to the 
user. An easy to interpret set of scores, “throughput” scores, is automatically created 
following each session. These scores are a combination of response time and number of 
correct responses. Higher scores indicate better performance. A table of the throughput 
scores for all of a subject’s sessions can be presented via the SCAT menu. Treatment test 
scores are compared to the subject’s basehelpre-test scores. Many other data points are 
also recorded during a session and those data are put into an ASCII text file where they 
can be exported to databases or statistical analysis programs. 
ARES is a s o h a r e  package for the Palm Operating System. It impliments a subset of 
WinSCAT testing. Response time, number of correct responses, and “throughput” 
scoring are scored similarly to WinSCAT. Compared with WinSCAT, it operates on 
Palm PDAs and is therefore more portable, and more desireable to use during spaceflight. 
Additionally, because it is a subset of WinSCAT, it is a shorter test to take. 
Statistical Analysis. All data from the two phases will be analyzed separately as well as 
collectively between sessions to identify effects of rnicrogravity on bioavailability and 
pharmacokinetics and saliva-to-plasma ratios. Pharmacokinetic parameters, e.g. 
absorption rate (Ka), bioavailability (F) and biological half-life (t1/2) derived from saliva 
and plasma concentrations-time profiles and ratio of plasma to saliva concentrations over 
the entire drug disposition period will be assessed using standard regression 
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methodology. In cases where the non-Gaussian distribution of a response variable 
precludes standard analysis of variance, a substitute analysis will be made using a 
generalized linear or nonlinear model with the appropriate distributional family 
(McCullogh and Nelder, 1989). These data will be also used to determine 
pharmacodynamic parameters e.g. time for onset of effect, minimum and maximum 
effect and duration of effect. These data will be further analyzed to determine the 
concentration-response and dose -response relationship of PMZ. 
The level of significance for all statistical tests will be 0.05. Estimates of statistical power 
for the study indicate that differences between treatment means of 20% can be detected 
for 8 subjects per treatment with power of >0.9 using analysis of variance on the 
WinSCAT performance parameters under the implied Gaussian assumption. However to 
allow for anticipated skewness of the distributions of some responses, we have increased 
our sample size to 12. Physiological effects of PMZ will be assessed by comparing data 
collected on all of the bioavailability and pharmacokinetic parameters from all sessions. 
Anticipated Conclusions. Results of this study will provide much-needed information on 
the pharmacokinetics, bioavailability, and pharmacodynamics of PMZ that may have a 
direct bearing on treatment with this drug for motion sickness during space flights. We 
expect to prove that the bioavailability of the three formulations of PMZ will be reduced 
during spaceflight (Hypotheses A and C). We expect that these changes in the 
pharmacokinetics and bioavailability of PMZ during ABR will be similar to the ones 
observed with acetaminophen and scopolamine during space flight. We will use these 
data for developing a pharmacokinetic model for PMZ that can estimate changes in these 
parameters of drug dynamics during space flight. We expect to validate ABR as a 
reliable ground-based microgravity analog for bioavailability and pharmacokinetic 
studies by comparing results of this study to those that will be collected from a similar 
investigation approved for flight manifestation. 
A significant relationship is expected between saliva and plasma concentrations that will 
be consistent between different doses and routes of administration, but the ratio of saliva 
to plasma may be different between ambulatory and ABR conditions (Hypothesis B). We 
expect a strong positive correlation between pharmacokinetic and pharmacodynamic 
parameters estimated from the plasma and saliva concentration data in both phases of the 
study. Finally, results of this study will provide a means for establishing noninvasive 
methods of pharmacodynamic and therapeutic assessment of neuroactive drugs 
(Hypothesis D). 
We expect that results from this study will serve as a basis for methods refinement and 
modification of an approved (NRA-96-OLMSA-0 1) flight protocol awaiting 
manifestation on future flights. 
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IX. Human Subjects. 
a. Detailed Description of Human Subjects. Twelve healthy, non-smoking subjects 
between the ages of 21 and 45 years will participate in the study. All subjects will be 
screened and selected through the subject recruitment facility of the appropriate institution 
(NASA Johnson Space Center or UTMB GCRC) according to the inclusion and exclusion 
criteria listed below. 
Inclusion criteria: 
1. Male or female 
2. Age 2 1-45 
3. 
4. General good health 
5. 
6. 
Normal weight for body size 
Renal and hepatic function within normal ranges 
Able to provide written informed consent to participate 
Exclusion criteria: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Drug allergies, especially to phenothiazine-type agents 
Use of prescription or over-the-counter medications within one week of starting 
the study 
Use of an investigational drug within 30 days of starting the study 
Tobacco smoking within the past year 
Blood donation or significant blood loss within 30 days of starting the study 
Significant gastrointestinal disorder, asthma, or seizure disorders 
History of alcohol or other drug abuse 
Pregnancy or suspected pregnancy, or lactation 
Treatment during menstruation will be avoided 
Hematocrit values less than 41% for males and 37% for females 
Aside fiom the criteria listed above, no subpopulations or special classes of subjects 
will be sought or avoided. 
b. Sources of Research Material. All material and data will be obtained 
specifically for research purposes. Samples of blood, saliva, and urine will be 
obtained fiom the subjects at specified times or intervals. Data obtained more 
directly will come from subjects taking the computerized WinSCAT and ARES 
tests to measure their cognitive performance, wearing an actiwatch that monitors 
their sleep and activity, and using the Space Therapeutic Assessment Recorder 
computer software to report on their sleepiness. 
c. Potential Risks. 
Stable isotope dosing: This study involves the use of non-radioactive forms of 
promethazine (PMZ) labeled with a stable isotope (deuterium). The use of these 
labeled forms of PMZ does not involve any greater risk to subjects than that with 
unlabeled PMZ. Deuterated isotopomers of drugs are used extensively in clinical, 
pharmaceutical, and biochemical research and have a very good safety record. 
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Blood sampling: All 4 sessions require multiple blood samples. To avoid repeated 
venipunctures, we will take samples from an Intra-CathB indwelling catheter placed in 
the antecubital vein at the beginning of each session. A separate venipuncture will be 
needed only for the sample at 72 hours after drug administration. The intracath will be 
removed at 72 hours to minimize the chance of infection at the injection site. A small 
risk of infection at the intracath site will remain, as well as a small risk of formation of a 
blood clot or hematoma associated with this procedure. The likelihood of any of these 
complications is remote. 
The volume of blood drawn from each subject will be about 126 ml over a 72-h period 
(1 8 times X 7 ml) and a total of 506 ml over the total period of the experiment (4 sessions 
over at least six months). A minimum of 7-d wash-out time will separate sessions or 
treatments. The body can replace 50 to 200 ml of whole blood in a 24-h period. Blood 
donation centers allow 1 unit (400 to 450 ml) of blood to be drawn every 8 weeks. Blood 
collection schedules used in this experiment protocol will fall within those guidelines. 
The total amount of blood withdrawn during one 72-h protocol is about 126 ml, and 
within one month a maximum of 252 ml, and is within the limits established by the 
American Association of Blood Banks. 
Drug administration: The total dose of PMZ for each session of this study is 37.5 mg. All 
of these doses are within the therapeutic range and are not expected to cause serious side 
effects. Common side effects are drowsiness, sedation, impaired psychomotor 
performance, and movement disorders. These effects are transient. No other known ill 
effects are expected from drug administration. Intramuscular injection of PMZ may cause 
some pain and irritation at the site of injection, and use of the suppository form of PMZ 
may cause rectal irritation. 
Adverse reactions and contraindications: Risks common to all drug administrations 
include allergic reactions and exacerbation of pre-existing conditions. We do not 
anticipate any serious reactions because this drug (PMZ) has been used clinically for 
many years. 
Side effects ofPMZ: Common side effects of PMZ are drowsiness, light-headedness, 
daytime sedation, dizziness, impaired psychomotor performance, and movement disorder. 
d. Recruitment and Consent. Subjects will be recruited through the human subject 
recruiting facility at either the NASA Johnson Space Center (JSC). If the JSC facilities 
are used, the study will first be verbally described to each potential subject by an 
employee of the recruiting facility, and preliminary questions will be asked to determine 
whether the subject is willing and suitable for this study. Potential subjects will attend a 
briefing session at which the principal investigator will describe the study in detail and 
present a written layman’s summary and consent form. The subjects will be encouraged 
to ask questions or to obtain further clarifications of the study purpose, risks, or 
procedures. Subjects will then be carefully screened for medical risk factors (Air Force 
Class I11 physical or equivalent). Once a subject has been medically cleared, a written 
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informed consent explaining procedures and monitoring will be obtained by the principal 
investigator. The informed consent document approved by the JSC Committee for the 
Protection of Human Subjects and the document submitted to the UTMB IRB for 
approval are attached. 
e. Protection Against Risk. A flight surgeon will be on call and available for 
consultation during the experiment. 
Blood sampling: Qualified technicians using appropriate equipment and precautions will 
carry out blood sampling procedures. Astronauts are trained in blood draw and catheter 
placement procedures and will perform the catheter placement and venipuncture 
procedures. The catheter will be fixed in place with a special tape and adhesive 
combination (Op-Site@). An antiseptic ointment will be applied at the intracath site to 
reduce the chance of infection. A heparin lock will be maintained to reduce the chance of 
clot formation or hematoma. Care will be taken to avoid injection of heparin into the vein 
by using just enough heparin (0.1 ml) to maintain a heparin lock, withdrawing residual 
volume from the intracath before sampling, and flushing the intracath with saline after 
each draw. 
Drug administration: Subjects will be briefed on PMZ side effects. Astronauts will 
be trained on the proper administration of the dosage forms. A physician will be on 
call for the rest of the study period. 
Adverse reactions and contraindications: Subjects will be medically screened for any 
pre-existing conditions and questioned during the pre-test physical about previous drug 
reactions and allergies. Female subjects are required to take a pregnancy test at the 
beginning of the study. At least one technician will have knowledge of the drug 
administered (placebo or PMZ) during each test. This information will be made available 
to the physician for medical treatment or evaluation of side effects. Intravenous solutions 
of saline or D5W will be available in the room for emergency use. Injectable 
diphenhydramine will be kept in the room for emergencies of idiosyncratic and allergic 
reactions due to drug administration. In the event of an unexpected reaction, a flight 
trained physician will be on hand for consultation. 
Side effects ofPMZ: The subjects will be briefed about side effects. They will be 
warned of the possible sedation effects of the drug. 
Protection ofconfidentiality: Confidentiality of all data will be maintained. 
Laboratory records will use any subject identifying information; rather, records will 
be assigned a numerical code, the decryption of which will be maintained by a 
minimal number of personnel. However, should a life-threatening abnormality be 
detected during the study, the investigator will notify the subject and the assigned 
JSC physician. Such information will be used for care and medical follow-up only. 
Each subject will be assured that his or her identity will not be released to the public 
without consent, unless specifically required by law. 
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f. Risks vs. Benefits. All the procedures used in the study are minimally 
invasive and pose minimal to reasonable risks to the subjects. However, the 
knowledge to be gained from the research will be important for the health of 
astronauts. The study will provide information about the dynamics and therapeutic 
index of promethazine during simulated microgravity conditions. This information 
will help flight surgeons determine the most appropriate means by which to 
administer promethazine, as well as help to determine specific physiological 
alterations induced by microgravity. Because many astronauts take promethazine to 
prevent space motion sickness, the results of this study will help maintain astronaut 
health and safety. 
g. Data Safety Monitoring Plan. 
1) Plan for safety review of data. We estimate the risk level of the study to be low. 
Vulnerable populations will not be included. The persons responsible for monitoring the 
safety environment of the participants will be the principal investigator, Lakshmi Putcha, 
Ph.D.; the medical monitor (physician). A Test Readiness Review Committee will 
convene before the study begins, to review safety precautions and procedures. After the 
nurse administers promethazine to a subject, a physician who can be present within 15 
min will be on call for the entire study period. Subjects will be released at the end of each 
study protocol after examination by the nurse and verbal approval of release by the 
attending physician. The study is expected to last 2 years (4 to 6 months for each subject). 
All key personnel involved with the study have completed training in the protection of 
human research participants mandated by the U.S. DHHS Office for Human Research 
Protections (OHRP). 
2) Plan for monitoring. All unanticipated or serious adverse events will be reported 
immediately to the Johnson Space Center (JSC) Committee for the Protection of 
Human Subjects (CPHS). An oral report will be given within 24 hours, and a 
written report within 48 hours of the event. 
3) Plan for assessing the degree of severity and attribution of adverse events. The 
medical monitor or alternate medical monitor of the study will grade any adverse 
event by the NASA JSC CPHS Adverse Event (AE) Grading Scale. The principal 
investigator will use the attribution scale (unrelated, possible, probable, or definite) 
to judge whether an adverse event is associated with a treatment or procedure used 
in the study. 
4) Plan for annual reporting of adverse events. An annual written report of any 
adverse events will be made to the JSC CPHS. 
X. Inclusion of Women and Minorities. Men and women of any race or ethnic 
background may be selected for the proposed study. All subjects will be screened and 
selected through the test subject recruitment facility of NASA JSC according to the 
inclusion and exclusion criteria listed below. 
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Inclusion criteria: 
1. Male or female 
2. Age 21-45 
3. 
4. 
5 .  
6. 
Normal weight for body size 
General good health, as determined by an Air Force Class I11 Flight Physical 
Renal and hepatic function within normal ranges 
Able to provide written informed consent to participate 
Exclusion criteria: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Drug allergies, especially to phenothiazine-type agents 
Use of prescription or over-the-counter medications within 3 days of starting the 
study 
Use of an investigational drug within 30 days of starting the study 
Tobacco smoking within the past year 
Blood donation or significant blood loss within 30 days of starting the study 
Significant gastrointestinal disorder, asthma, or seizure disorders 
History of alcohol or other drug abuse 
Pregnancy or suspected pregnancy, or lactation 
Treatment during menstruation will be avoided 
Hematocrit values less than 41% for males and 37% for females 
Aside from the criteria listed above, no subpopulations or special classes of subjects 
will be sought or avoided. 
Subjects will be enrolled for at least six months each beginning in March 2005. 
XI. Inclusion of Children. The research topic is irrelevant to children. The 
knowledge to be gained from the research will be important for the health of 
astronauts, all of whom are adults. The study is designed to investigate differences 
in bioavailability as a function of route of administration and to establish 
noninvasive methods for assessing pharmacodynamics of promethazine. This 
information will help flight surgeons determine if astronauts may have side effects 
after receiving promethazine by one of three different routes of administration. 
Because many astronauts take promethazine to prevent space motion sickness, the 
results of this study will help maintain astronaut health and safety. Therefore, the 
subject population of the study models that of the astronaut corps to address the 
needs of this very specific population. 
XII. Use of the General Clinical Research Center. 
a. Laboratory investigations. 
1. Investigators’ laboratories. All analyses of samples and of data from the 
actigraphs and WinSCAT test battery will be performed in the investigators’ laboratories. 
Concentrations of promethazine (PMZ) and its metabolites in blood plasma, saliva, and 
urine will be determined with a modified liquid chromatographic-mass spectrometry (LC- 
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MS) method. This method uses an on-line solid-phase extraction coupled with the LC- 
MS system. Concentrations of PMZ, PMZ sulfoxide, desmethyl PMZ sulfoxide, and 
desmethyl PMZ will be determined in plasma and urine; PMZ and PMZ sulfoxide will be 
determined in saliva. Concentration vs. time curves will be generated for the unlabeled 
and stable-isotope-labeled PMZ analogs, and their respective metabolite(s) in plasma and 
urine, and these data will be analyzed by exponential stripping and parametric 
estimations using standard pharmacokinetic data analysis programs. Absorption and 
elimination rates will be calculated using noncompartmental parametric estimation 
methods. Bioavailability will be calculated from the area under the plasma and saliva 
concentration-time curves of the parent compounds using WinNonlin software. Sleep and 
activity variables (percent daytime activity, sleep latency, wake after sleep onset, duration 
and efficiency) will be calculated fiom actigraph data, and the effect of PMZ on these 
variables will be evaluated. These objective sleep data will be compared with the data 
from subjective sleep logs (Karolinska Sleepiness Score, KSS). After each WinSCAT 
and ARES session, an easy-to-interpret set of scores, "throughput" scores, is 
automatically created. These scores are a combination of response time and number of 
correct responses. Higher scores indicate better performance. A table of the throughput 
scores for all of a subject's sessions can be presented via the SCAT or ARES menu. 
Treatment test scores are compared to the subject's baseline/pre-test scores. 
Pharmacodynamic effect(s) as a function of drug concentration will be assessed using 
results from the WinSCAT and ARES test scores, actigraphy, KSS data, and 
physiological data. Standard pharmacodynamic analytical methods will be used to 
estimate onset, duration, and extent of effect, time for minimum and maximum effect, 
and dose-response relationship of the drug. 
2. Hospital laboratories. Not anticipated. 
3. Outside laboratories. Not anticipated. 
XII. Grant or contract support. Please see the attached form. 
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